Drug Profile
Interferon gamma biobetter - Biolingus
Alternative Names: Interferon gamma sublingual - Biolingus; Project A2 (SLIT) - BiolingusLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Biolingus
- Class Antiparasitics; Biobetters; Interferons; Lymphokines
- Mechanism of Action Interferon gamma stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Leishmaniasis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Leishmaniasis in Switzerland (Sublingual)
- 18 Sep 2017 Interferon gamma biobetter - Biolingus is available for licensing as of 18 Sep 2017. http://www.biolingus.ch/index.html#partners
- 18 Sep 2017 Preclinical trials in Leishmaniasis in Switzerland (Sublingual) before September 2017 (Biolingus pipeline, September 2017)